BioSyent (CVE:RX) Reaches New 12-Month High – Here’s Why

BioSyent Inc. (CVE:RX)’s share price hit a new 52-week high on Tuesday . The company traded as high as C$15.21 and last traded at C$15.21, with a volume of 2320 shares trading hands. The stock had previously closed at C$14.66.

Analyst Upgrades and Downgrades

Separately, Bloom Burton upgraded BioSyent from a “moderate buy” rating to a “strong-buy” rating in a research note on Friday, November 21st. One analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of “Strong Buy”.

BioSyent Stock Performance

The stock’s 50 day moving average price is C$13.43 and its two-hundred day moving average price is C$12.20. The company has a current ratio of 3.92, a quick ratio of 6.91 and a debt-to-equity ratio of 2.90. The firm has a market capitalization of C$171.99 million, a price-to-earnings ratio of 20.41 and a beta of 0.52.

BioSyent Company Profile

BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.